A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234) - Takeaways - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)
Can we lower the chance of gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into the abdominal cavity in addition to chemotherapy given through a vein in the arm? Will administering paclitaxel chemotherapy directly into the abdominal cavity, in addition to chemotherapy given through a vein in the arm help patients live longer?
STOPGAP II (EA2234; NCT07001748) is a randomized phase II/III trial in gastric and gastroesophageal junction adenocarcinoma with peritoneal carcinomatosis.
2
The trial compares intraperitoneal paclitaxel plus systemic treatment with systemic treatment alone.
3
The study evaluates whether adding paclitaxel directly into the abdominal cavity can reduce the chance of gastric cancer growth or spread.
4
The trial also evaluates whether intraperitoneal paclitaxel added to intravenous chemotherapy helps patients live longer.
5
The study aims to determine whether this approach is better or worse than the usual treatment approach for gastric cancer.